Aptevo Therapeutics Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
2401 4TH AVE., SEATTLE, WA, 98121
Mailing Address
2401 4TH AVE., SEATTLE, WA, 98121
Phone
206-838-0500
Fiscal Year End
1231
EIN
811567056
Financial Overview
FY2025
-$24.13M
Net Income
$27.19M
Total Assets
$17.38M
Stockholders' Equity
$21.62M
Cash & Equivalents
$-87.27
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 26, 2026 | View on SEC |
| 10-K Annual financial report | March 26, 2026 | View on SEC |
| 8-K Current report of material events | March 11, 2026 | View on SEC |
| 8-K Current report of material events | February 19, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| 8-K Current report of material events | February 3, 2026 | View on SEC |
| 424B4 Prospectus for IPO or offering | January 30, 2026 | View on SEC |
| S-1 IPO registration statement | January 28, 2026 | View on SEC |
| DEF 14A Definitive proxy statement | January 26, 2026 | View on SEC |
Annual Reports
10-K
March 26, 2026
- Lead drug Mipletamig shows 86% clinical benefit and 79% remission in leukemia patients.
- Proprietary ADAPTIR and ADAPTIR-FLEX platforms enable highly targeted immunotherapy.
Material Events
8-K
Leadership Change
March 26, 2026
High Impact
- Promising clinical data for mipletamig (APVO442) showing an 86% clinical benefit rate in AML patients.
- Strong safety profile with zero cases of severe cytokine release syndrome.
8-K
Leadership Change
February 3, 2026
High Impact
- Planned and orderly leadership transition ensures continuity with former CEO Marvin L. White transitioning to Executive Chair.
- Internal promotion of Jeff Lamothe (COO, former CFO) to President and CEO brings strong financial and operational expertise.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.